{
    "nct_id": "NCT00829816",
    "title": "A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)",
    "status": "COMPLETED",
    "last_update_time": "2015-11-06",
    "description_brief": "The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine)"
    ],
    "placebo": [
        "Not specified in the provided description"
    ],
    "explanation_target": [
        "Reason: The trial tests dimebon (latrepirdine), an oral small-molecule drug originally developed as an antihistamine that was investigated for symptomatic cognitive benefits and neuroprotective actions in Alzheimer's disease rather than as a biologic targeting amyloid or tau. \ue200cite\ue202turn0search12\ue202turn0search3\ue201",
        "Act: Extracted details \u2014 drug name: Dimebon (latrepirdine); intervention type: small-molecule (non-biologic); trial goal: safety/tolerability in AD patients on memantine or memantine+donepezil. Dimebon has been described in the literature as a putative cognitive enhancer/nootropic with proposed mitochondrial/neuroprotective mechanisms, and earlier clinical studies looked at cognitive endpoints (ADAS-cog, MMSE) and behavior. \ue200cite\ue202turn0search2\ue202turn0search6\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 definitions: (1) disease-targeted biologic = biologic (e.g., mAb) against AD pathology (not applicable); (2) disease-targeted small molecule = small-molecule that directly targets pathology (e.g., BACE inhibitors) \u2014 dimebon does not have a well-defined anti-amyloid/tau target; (3) cognitive enhancer = drugs that improve cognitive function without a specific disease-targeted biologic mechanism \u2014 best fit for dimebon; (4) neuropsychiatric symptom improvement = targets behavioral symptoms specifically (dimebon showed some NPI effects but was primarily studied for cognition). Therefore the correct category is \"cognitive enhancer.\" Note: dimebon was later evaluated in larger phase 3 trials with mixed/negative efficacy results despite initial positive signals; it is not a biologic. \ue200cite\ue202turn0search3\ue202turn0search2\ue202turn0search6\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The trial tests Dimebon (latrepirdine), an oral small-molecule repurposed antihistamine investigated as a symptomatic cognitive enhancer with putative neuroprotective effects (mitochondrial modulation, receptor modulation, autophagy), not a biologic directed at amyloid or tau. This profile maps best to CADRO category M (Synaptic Plasticity / Neuroprotection). \ue200cite\ue202turn0search0\ue202turn0search8\ue201",
        "Act: Extracted details \u2014 drug: Dimebon (latrepirdine); intervention: small-molecule cognitive enhancer/nootropic given with memantine \u00b1 donepezil in AD; proposed mechanisms include multireceptor modulation (AMPA/NMDA/serotonergic/adrenergic), weak cholinesterase effects, mitochondrial/mitochondrial permeability transition pore effects, modulation of autophagy and intracellular calcium \u2014 all consistent with actions on synaptic function and neuronal resilience rather than a single amyloid/tau molecular target. \ue200cite\ue202turn0search12\ue202turn0search1\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 dimebon is not a disease-targeted biologic (not A or B) nor a clear single-pathway anti-amyloid/tau small molecule; its intended use was symptomatic cognitive enhancement and putative neuroprotection, so M) Synaptic Plasticity/Neuroprotection is the most specific CADRO match. An alternate plausible mapping could emphasize mitochondrial actions (J) Metabolism and Bioenergetics, but because the clinical framing and preclinical literature focus on cognition and synaptic/neuroprotective effects, M is preferred. Phase-3 clinical outcomes were ultimately negative/neutral, but that does not change the drug\u2019s mechanistic classification. \ue200cite\ue202turn0search7\ue202turn0search2\ue201",
        "Web search results (sources used): (1) Latrepirdine review summarizing multireceptor, mitochondrial and neuroprotective actions (PubMed). \ue200cite\ue202turn0search0\ue201 (2) Study showing latrepirdine alters extracellular A\u03b2 and modulates neurotransmission (Molecular Neurodegeneration). \ue200cite\ue202turn0search1\ue201 (3) Mount Sinai summary / autophagy and APP metabolism work showing effects on autophagy and A\u03b2 neuropathology in models. \ue200cite\ue202turn0search3\ue201 (4) Systematic review of preclinical latrepirdine studies noting multiple targets (mitochondria, AChE, NMDA/calcium). \ue200cite\ue202turn0search8\ue201 (5) Press releases / reports of Phase 3 results and program discontinuation (Pfizer/Medivation, commentary). \ue200cite\ue202turn0search2\ue202turn0search7\ue201"
    ]
}